Last week, the J.P. Morgan Healthcare Conference once again gathered investors, analysts, bankers, and corporate teams in San Francisco to kick off the year with critical updates and discussions that will ultimately shape the future market. As a first look into 2026, the conference delivered valuable insights into trends, guidance, and expectations across MedTech, Biotech, Life Science Tools & Diagnostics (LSTDx), and Digital Health/HCIT. Below, our team is recapping the key takeaways from each sector and sharing insights around what we saw and heard this year.
MedTech Key Takeaways
The 2026 J.P. Morgan Healthcare Conference reinforced a central theme for MedTech: fundamentals remain solid, but capital allocation and regulatory dynamics are shifting in ways that demand attention from management teams. Large-cap device companies emphasized steady procedure growth and pipeline execution across imaging, structural heart, and neuro, while signaling greater margin discipline over top-line acceleration. AI dominated the conversation but has clearly evolved from buzzword to “show me the ROI.” Perhaps the most significant validation of MedTech value creation came in the conference’s final day when Boston Scientific announced its agreement to acquire Penumbra at approximately $14.5 billion, reflecting an EV multiple of ~9x 2026E sales and ~57x EV/2026E EBITDA. This valuation was meaningfully above the five-year average MedTech transaction multiple of ~7x forward sales. Analyst reaction was decidedly positive for the sector, with commentary noting that the premium validates the attractive nature of high-growth SMID MedTech assets. Penumbra’s pre-announced Q4 results underscored the strength justifying that premium, with revenue of $383-385 million representing a 6% beat and 21-22% year-over-year growth.
More broadly, the Q4 pre-announcement season at JPM delivered encouraging results across the 35+ companies reporting preliminary figures:
- Notable beats: Glaukos (+10.5%), Intuitive Surgical (+5.4%), RxSight (+18.2%), and NeuroPace (+9.1%)
- Notable misses: Teleflex (CEO transition-related), Enovis, and Inogen (order timing shift)
- 2026 guidance initiations meeting or exceeding expectations: Globus Medical, Alphatec, AtriCure, Inspire Medical, iRhythm, and Senseonics
Despite Boston Scientific’s acquisition of Penumbra, strategics framed 2026 as a period of disciplined but active deal-making with “significant firepower” targeting tuck-ins around AI, structural heart, neuromodulation, and higher-growth niches. Regulatory panels flagged AI/digital guidance, BIOSECURE-related supply chain scrutiny, and evolving MDR/eIFU rules as front-of-mind considerations, with FDA signaling more clarity coming in 2026 on AI and device software alongside tougher expectations on quality and change control for Class III manufacturing.
The practical takeaway for management teams: investors want to see operating leverage, clear AI monetization pathways, and credible, bite-sized M&A before re-rating MedTech back to prior multiples, positioning the sector as a “show me” trade where execution and free cash flow generation will differentiate winners from laggards.
Authored by: Greg Chodaczek, Managing Director (MedTech), Gilmartin Group
Biotech Key Takeaways
The hopeful mood at J.P. Morgan this year, bolstered by the sunshine, was tempered by the lack of the anticipated series of large M&A announcements. The week opened with news of AbbVie’s multibillion-dollar deal to acquire Remegen’s RC-148, but overall, there were fewer headline-grabbing announcements made on day one of the conference. Cautious optimism, however, was a sentiment expressed by many, with hope that Biotech continues its strong performance. IPOs over the next 12 to 18 months could feel like a flood after last year’s dribble, as the number of companies looking to IPO continues to grow. With one more year to mature, analysts are generally optimistic that higher quality companies will turn into higher quality deals.
After nearly 2,500 meetings this week that took place at the 2026 Gilmartin Corporate Access event, investors have expressed they want to see clarity in the regulatory path forward, differentiation of a company’s asset, realistic milestones, and an ability to operate through the milestones. We are cautiously optimistic that this pragmatic approach to Biotech could lead to fundamentally sustainable performance this year.
Authored by: Monique Kosse, Managing Director (Biotech), Gilmartin Group
Life Science Tools & Diagnostics Key Takeaways
In the LSTDx space, broad sentiment has improved coming out of the conference; the vast majority of companies who pre-announced Q4 results beat consensus.
- Tools: Several Tools companies provided more optimistic commentary on 2026 in terms of end-markets, with biopharma and biotech trending better than academic and government. Tools companies pointed to improved biopharma spending in the fourth quarter, with strong consumables demand and improved instrument demand commentary, including some companies seeing a year-end budget flush. Meanwhile, management teams noted muted demand in the academic and government end-market, which has largely stabilized, but remain cautious due to continued budget uncertainty (several companies have pointed to flat-to-slightly positive budget expectation in 2026). China also remains uncertain coming out of the conference, though several Tools players have noted signs of stabilization in the region and a tone of cautious optimism on recovery in 2026.
- Diagnostics: Diagnostics companies broadly beat consensus, with positive commentary on volume growth, ASPs driven by reimbursement decisions, and new product developments and launches. Natera, Guardant Health, and Caris Life Sciences had particularly strong preliminary revenue and volume growth. Despite the large number of beats, stock reactions were mixed due to high expectations, along with true-up dynamics contributing to results (some companies, like Caris Life Sciences, benefitted from true-up revenue in Q4).
- Pre-Announcements and Guidance: Q4 pre-announcement results in the Life Science Tools and Diagnostics space were largely positive, with 25 of the 31 companies who pre-announced (81%) beating consensus by an average of 7%. By sub-sector, all three diversified tools/dx companies who pre-announced beat consensus, while 8 of 10 growth tools companies, and 14 of 17 growth diagnostics companies beat consensus. On FY26 guidance, 7 companies initiated guidance (all diagnostic companies), with revenue expectations set above consensus.
Authored by: Gabby Gabel, Associate (LSTDx), Gilmartin Group
Digital Health & HCIT Key Takeaways
In the HCIT space, key topics of discussion included policy & legislation (including OBBBA), AI, GLP-1s, and more. Results were mostly in-line or slightly ahead of expectations, with several companies setting up for a beat-and-raise cadence by issuing conservative 2026 outlooks. Analysts highlighted that stock performance across some SMID-cap names was disconnected from mostly positive pre-announcements, as investors weigh new information and potential risks to 2026 performance. Notable news throughout the week included Anthropic introducing Claude for Healthcare, their proprietary AI tool targeting providers, payers, and consumers, and positive pre-announcements from Omada and Cardinal Health.
Policy continues to impact the sector, with distributors discussing the IRA’s impact on WAC negotiations for 2026, while others spoke about reimbursement pressures in home healthcare. HealthEquity pointed out several expansion provisions for HSA plans as a result of OBBBA. AI was also popular topic across various companies and business models, as companies discussed process automation, scribing, and data management as key applications of the technology. GLP-1 volume was described as growing fast, but at a lower margin for distributors. Elsewhere, companies like Progyny and HealthEquity discussed adding GLP-1s to their offerings given the amount of interest and consumer spending on such products.
Sentiment exiting the conference remains largely neutral, as reflected in stock performance throughout the week. There are signs of stability and optimism across some groups such as distributors, but overall uncertainty as investors look to understand the implications of an evolving macroeconomic environment and policy developments. Throughout 4Q earnings season, the street will look for additional color on external factors driving 2026 guidance, and an update on trends observed throughout the first 2 months of the year.
Authored by: Matt Scileppi, Associate (LSTDx, Digital Health & HCIT), Gilmartin Group
In Conclusion
The 2026 J.P. Morgan Healthcare Conference reinforced a more disciplined, execution-driven outlook across healthcare sectors. While enthusiasm around innovation, AI, and long-term growth remains, investor focus has clearly shifted toward proof points—operating leverage, capital efficiency, regulatory clarity, and credible paths to value creation. Across MedTech, Biotech, Life Science Tools & Diagnostics, and Digital Health & HCIT, companies that paired strong fundamentals with clear milestones, realistic guidance, and tangible ROI stood out, underscoring a market that is increasingly selective but constructively engaged.
At Gilmartin, we’re excited to continue supporting our clients as they navigate these trends and position themselves for success in the year ahead. The team at Gilmartin Group has extensive experience working with both private and public companies across the MedTech, Biotech, Life Science Tools & Diagnostics, Digital Health & HCIT sectors. To find out more about how we strategically partner with our clients, please do not hesitate to contact our team today.